866-997-4948(US-Canada Toll Free)

Cariprazine Analysis and Forecasts from 2013 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 26 Pages


GlobalDatas pharmaceuticals report, Cariprazine Analysis and Forecasts from 2013 to 2020 provides Cariprazine sales estimates for US and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Schizophrenia market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Cariprazine including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Cariprazine including efficacy, safety, pricing and other details which influence its sales potential
  • Detailed sales forecast for 2013-2020 for Cariprazine in the US and Japan
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Schizophrenia 4
2.2 Symptoms 4
2.3 Schizophrenia Market 4
2.4 Epidemiology 4
2.5 Etiology 5
2.5.1 Genetic Factors 5
2.5.2 Environmental Factors 5
2.5.3 Abnormal Brain Structure 6
2.6 GlobalData Report Guidance 6

3 Schizophrenia: Market Characterization 7
3.1 Schizophrenia Market 7
3.2 Schizophrenia Market Forecasts and CAGR 7
3.3 Drivers of Schizophrenia Therapeutics Market 8
3.3.1 Patent Expiry of Leading Marketed Drugs 8
3.3.2 Increasing Patient Pool 8
3.3.3 High Prescription Rates 8
3.3.4 Low Patient Compliance Rate 8
3.3.5 High Unmet Need 8

4 Classification of Schizophrenia 9
4.1 Age of Onset of Schizophrenia 9
4.1.1 Pediatric / Adolescent / Childhood Schizophrenia 9
4.1.2 Adult Schizophrenia 10
4.2 Associated Symptoms 10
4.2.1 Paranoid Schizophrenia 10
4.2.2 Disorganized Schizophrenia 10
4.2.3 Catatonic Schizophrenia 10
4.2.4 Residual Schizophrenia 10
4.2.5 Undifferentiated Disorder 10

5 Treatment for Schizophrenia 11
5.1 Crisis Resolution Teams (CRT) 11
5.2 Voluntary and Compulsory Detention 11
5.3 Antipsychotics 11
5.3.1 Typical Antipsychotics 11
5.3.2 Atypical Antipsychotics 12
5.3.3 Increased Mortality in Elderly Patients with Dementia-Related Psychosis 12

6 Cariprazine 13
6.1 Introduction 13
6.2 Mechanism of Action 13
6.3 Clinical Studies 13
6.4 Cariprazine Drug Development Status 14
6.5 Factors Affecting Sales of Cariprazine 15
6.5.1 Unique Receptor Binding Properties 15
6.5.2 High Competition 15
6.5.3 Collaborations 15
6.5.4 Lack of Presence in EU 15
6.6 Drug Evaluation 16
6.6.1 Drug Risk Benefit Score 16
6.6.2 Intensity of Competition 16
6.7 Sales Forecasts 18
6.7.1 Target Patient Pool of Cariprazine 18
6.7.2 Dosing 18
6.7.3 Market Penetration 18
6.7.4 Annual Cost of Therapy 18
6.7.5 Sales Projections of Cariprazine 19

7 Schizophrenia Market: Appendix 23
7.1 Market Definitions 23
7.2 Abbreviations 23
7.3 Research Methodology 23
7.4 Drug Sales Estimates Model 25
7.5 Contact Us 26
7.6 Disclaimer 26
7.7 Sources 26

List of Table


Table 1: Cariprazine, Phase IIb Clinical Trials Results 14
Table 2: Cariprazine, Drug Development Status, 2010 15
Table 3: Drug Risk Benefit Score of Cariprazine 16
Table 4: Competitors of Cariprazine 17
Table 5: Cariprazine, Schizophrenia, Global, Sales Forecasts ($m), 20132020 19
Table 6: Cariprazine, Schizophrenia, The US, Sales Forecasts ($m), 20132020 20
Table 7: Cariprazine, Schizophrenia, Japan, Sales Forecasts ($m), 20162020 21

List of Chart


Figure 1: Risk of Developing Schizophrenia 5
Figure 2: Environmental Factors in the Development of Schizophrenia 6
Figure 3: Schizophrenia, Global, Market Size Forecasts ($bn), 20102020 7
Figure 4: Classification of Schizophrenia based on the Age of Disease Onset 9
Figure 5: Reduction in PANSS Scores for Atypical Antipsychotics 17
Figure 6: Drug Model Diagram of Cariprazine 18
Figure 7: Cariprazine, Schizophrenia, Global, Sales Forecasts ($m), 20132020 19
Figure 8: Cariprazine, Schizophrenia, The US, Sales Forecasts ($m), 20132020 20
Figure 9: Cariprazine, Schizophrenia, Japan, Sales Forecasts ($m), 20162020 21
Figure 10: Cariprazine, Schizophrenia, Global, Sales Distribution in Major Countries (%), 2020 22

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *